{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:17:34Z","timestamp":1783030654585,"version":"3.54.6"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Skin Research and Technology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral supplementation with some amino acids (like methionine, taurine, and cysteine) could be useful in subjects with hair loss conditions such as androgenic alopecia (AGA or FAGA) or telogen effluvium (TE). Hydrolysed collagen (HC) oral supplementation has demonstrated to have beneficial effects on nail and skin health and could improve hair growth. A food supplement in tablet formulation containing hydrolysed fish\u2010origin collagen (300\u00a0mg\/dose), taurine, cysteine, methionine, iron, and selenium has been recently available. To date no controlled data are available regarding the clinical efficacy of this product as adjuvant to hair loss specific treatments in these clinical conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study aims<\/jats:title>\n                    <jats:p>To evaluate and compare the efficacy and tolerability of an oral supplementation based on HC and amino acids in subjects with hair loss due to AGA\/FAGA or chronic TE in combination with drug treatments in comparison with drug treatments alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and subjects<\/jats:title>\n                    <jats:p>\n                      In a prospective, 12\u2010week, randomized, assessor\u2010blinded controlled trial 83 subjects (mean age 41\u00a0\u00b1\u00a016 years; 26 men and 57 women) were enrolled in the study. Fifty\u2010nine subjects suffered from AGA\/FAGA (Hamilton I\u2010VA, Ludwig I\u20101, II\u20102) and 24 from chronic TE. Subjects were randomized to oral supplementation (1 tablet day) in combination with the specify drug treatment decided by the investigator according to the type of hair loss (AGA\/FAGA or TE) (Group A;\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a048) or to specific drugs treatment only (Group B;\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a035). The main outcome of the trial was the clinical efficacy evaluation using a 7\u2010point global assessment score (GAS) (from +3: Much Improved to \u20103 Much worsened; with score 0 representing no modification). The GAS score was evaluated using standardized photographs by an investigator unaware of the treatment groups at week 6 and at week 12. A secondary outcome was the evaluation of acceptability of the treatment regimen using a 10\u2010point evaluation score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy\u2010six participants (91.6%) completed the 12\u2010week study period. The GAS score at week 6 was 0.5\u00a0\u00b1\u00a00.2 in group A and 0.0\u00a0\u00b1\u00a00.1 in Group B (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05; Mann\u2010Whitney). At week 12 the GAS score in Group A was statistically significant higher in comparison with Group B (1.67\u00a0\u00b1\u00a00.16 and 0.66\u00a0\u00b1\u00a00.20,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001; Mann\u2013Whitney test). A higher percentage of Group A subjects achieved a GAS score of \u22652 in comparison with group B (50%\u00a0vs. 23%). The oral supplement was generally well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An oral supplement containing hydrolysed fish\u2010origin collagen, taurine, cysteine, methionine, iron, and selenium has demonstrated to improve the clinical efficacy of specific anti\u2010hair loss treatments in subjects with AGA\/FAGA or chronic TE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/srt.13381","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T18:00:03Z","timestamp":1686160803000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3\u2010month, controlled, assessor\u2010blinded study"],"prefix":"10.1111","volume":"29","author":[{"given":"Massimo","family":"Milani","sequence":"first","affiliation":[{"name":"Medical Department Cantabria Labs Difa Cooper  Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8099-0192","authenticated-orcid":false,"given":"Francesca","family":"Colombo","sequence":"additional","affiliation":[{"name":"Medical Department Cantabria Labs Difa Cooper  Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GFM\u2010O\u2010Trial Investigators Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169116"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.07.001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.01.007"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.008"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.29011\/2575\u20108268.100199"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.111.6.2587"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2007.02.005"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpn.13238"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467\u20102494.2006.00334.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155\u20109600.s5\u2010002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.17470\/NF\u2010020\u20100019"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911904"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15344"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7241\/ourd.20183.25"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010018\u20100278\u20106"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733\u20108635(05)70397\u20101"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190\u20109622(98)70007\u20106"},{"key":"e_1_2_10_19_1","first-page":"659","article-title":"Reproducibility of global photographic assessments of patients with male pattern baldness in a clinical trial with finasteride [abstract]","volume":"104","author":"Kaufman K","year":"1995","journal-title":"J Invest Dermatol"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.12937661"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.539"}],"container-title":["Skin Research and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/srt.13381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/srt.13381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/srt.13381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:53:23Z","timestamp":1780642403000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/srt.13381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/srt.13381"],"URL":"https:\/\/doi.org\/10.1111\/srt.13381","archive":["Portico"],"relation":{},"ISSN":["0909-752X","1600-0846"],"issn-type":[{"value":"0909-752X","type":"print"},{"value":"1600-0846","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2023-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13381"}}